Evotec (EVT) – aksjekurser og nyheter

Hvorfor har EVT gått ned? 2,77%?

Gå mer i dybden

EVT:ETR

Evotec

2,94 €

−2,77%

(−0,084) 1 D

2. okt., 14:20:52 GMT+2 · EUR

Alle symboler

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for EVT …

Åpne

3,05 €

Høy

3,05 €

Lav

2,93 €

Markedsverdi

524,33 mill.

Snittvolum

909,90k

Volum

236,36k

52 u høy

7,30 €

52 u lav

2,71 €

EPS

−1,11 €

Utestående aksjer

177,91 mill.

Antall ansatte

Åpne

3,05 €

Høy

3,05 €

Lav

2,93 €

Markedsverdi

524,33 mill.

Snittvolum

909,90k

Volum

236,36k

52 u høy

7,30 €

52 u lav

2,71 €

EPS

−1,11 €

Utestående aksjer

177,91 mill.

Antall ansatte

Nyhetssaker

Fra nettkilder og nyhetspartnere

AD HOC NEWS

for 1 døgn siden

Evotec loses science chief. Evotec stock falls 1.28 percent

Profil

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia

Om Evotec

Administrerende direktør-

Ansatte4,46k

Grunnlagt1993

Hovedkontor-

Sektor-

Nettstedevotec.com

Alle verdier i EUR	sep. 2025	des. 2025	mars 2026	juni 2026
Inntekt	163,89 mill.	253,27 mill.	156,64 mill.	143,48 mill.
Varekostnad	163,95 mill.	174,81 mill.	158,21 mill.	145,06 mill.
Direkte driftskostnader	163,95 mill.	174,81 mill.	158,21 mill.	145,06 mill.
Utgifter til forskning og utvikling	8,71 mill.	9,83 mill.	10,08 mill.	10,26 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	42,31 mill.	44,35 mill.	43,79 mill.	39,29 mill.
Driftskostnader	43,53 mill.	55,25 mill.	44,85 mill.	87,74 mill.
Totale driftskostnader	207,48 mill.	230,06 mill.	203,07 mill.	232,80 mill.
Driftsinntekter	−43,59 mill.	23,21 mill.	−46,42 mill.	−89,32 mill.
Andre ikke-operasjonelle inntekter	1,19 mill.	−33,96 mill.	1,89 mill.	−839,00k
EBT inkludert uvanlige elementer	−42,96 mill.	29,46 mill.	−122,18 mill.	−48,12 mill.
EBT uten uvanlige elementer	−43,36 mill.	18,35 mill.	−47,40 mill.	−94,00 mill.
Kostnad for inntektsskatt	127,00k	14,84 mill.	−244,00k	−1,47 mill.
Faktisk avgiftssats	−0,30 %	50,37 %	0,20 %	3,06 %
Andre driftskostnader	−7,50 mill.	1,07 mill.	−9,02 mill.	38,20 mill.
Nettoinntekt	−43,09 mill.	14,62 mill.	−121,94 mill.	−46,65 mill.
Netto fortjenestemargin	−26,29 %	5,77 %	−77,84 %	−32,51 %
Resultat per aksje	−0,24	-	-	-
Rente- og investeringsinntekter	841,00k	11,84 mill.	-	-
Rentekostnader	−2,28 mill.	-	−2,58 mill.	−2,97 mill.
Netto rentekostnader	−1,44 mill.	11,84 mill.	−2,58 mill.	−2,97 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	−18,27 mill.	41,91 mill.	−22,60 mill.	−64,88 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

Finance

Spør om hva som helst